CORDIS
EU research results

CORDIS

English EN

A novel technology enabling efficient delivery of personalized probiotics to prevent gut-related diseases and recover damaged gut microbiota

Project information

Grant agreement ID: 945936

Status

Ongoing project

  • Start date

    1 June 2020

  • End date

    31 May 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 2 851 000

  • EU contribution

    € 1 995 700

Coordinated by:

MYBIOTICS PHARMA LTD

Israel

Objective

Gut-microbiome is an essential part of human health. Gut bacteria imbalance is now recognized as a crucial factor in the development of many diseases – chronic, obesity, diabetes, liver, cardio, cancer and neurodegenerative. Traditional probiotics used today, aimed at restoring this imbalance, are not effective: They are incapable of delivering sufficient number and variety of bacteria to the correct location in the gut and have them colonize. MyBiotics, a microbiome company, developed a novel technology for very efficient growth, delivery, and colonization of needed bacteria types in the gut. The technology uses innovative fermentation methods to grow complex bacteria communities on micro-particles, dry it to powder and place into capsules administered like any probiotic supplement. MyBiotics proved the technology for single-strain-bacteria and for replicating multi-strain biological samples. In this project it is introducing MBSelect, which will remove the reliance on a biological sample and add formulation of multi-strain communities of human bacteria, grown in pre-selected clusters in any combination. The MBSelect innovation enables, for the first time, the creation of personalized, microbiome-based probiotics, fitted to any purpose – recovery from illness, chronic condition, or as supplements – and fitted to specific microbiome needs of different ethnicities, age, and gender. MyBiotics won and executed a Phase1 feasibility study in 2015, which served as a basis for its development since and for this project application. MyBiotics’ objectives in this project are to complete the development of the MBSelect technology, develop its first three probiotic products, scale them to industrial level, test them, and produce the 1st batch for initial commercial market testing immediately following the project; followed by full EU & US commercialization and scaling. The success of MBSelect is key in realizing the potential of MyBiotics and enabling the company to grow.

Coordinator

MYBIOTICS PHARMA LTD

Address

5 Golda Meir Blvd, Rth Floor
7414001 Ness Ziona

Israel

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 995 700

Project information

Grant agreement ID: 945936

Status

Ongoing project

  • Start date

    1 June 2020

  • End date

    31 May 2022

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 2 851 000

  • EU contribution

    € 1 995 700

Coordinated by:

MYBIOTICS PHARMA LTD

Israel